Issue Date: November 27, 2017
The RNA drug hunters
Matthew Disney has spent much of the past 12 years countering doubtful, sometimes even dismissive, remarks about his work. Fellow academic researchers said his science was too risky; federal agencies were reluctant to fund it. His friends in industry said there simply weren’t enough data.
Why the skepticism? The Scripps Research Institute Florida chemist has been trying to do something that defies drug discovery dogma: Invent small-molecule drugs that can target RNA.
Almost every pill . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society